What is Regeneron Pharmaceuticals's lynozyfic — revenue?

Regeneron Pharmaceuticals (REGN) reported lynozyfic — revenue of $16.5M in Q2 2026.

What does lynozyfic — revenue mean?

This metric represents the total net sales generated from the Lynozyfic product line within the company's portfolio. It reflects the market adoption, pricing power, and commercial success of this specific therapeutic asset in its targeted disease indications. Tracking these revenues allows investors to assess the product's contribution to the overall top-line growth and its lifecycle stage within the competitive pharmaceutical landscape.

Regeneron Pharmaceuticals (REGN) Lynozyfic — Revenue

Screener

Other product segments

Other products

$0—

Similar metrics at other companies

HRO

HROWOther Revenues — Revenue

$73K-15.1%

ORCLCloud Revenues — Revenue

$9.91B+47.1%

ORCLSoftware Revenues — Revenue

$6.82B-2.1%

OWLPerformance revenues — Revenue

$6.07M-3.9%

EAT

EATFranchise revenues — Revenue

$14.7M+21.5%

CNKOther Revenues — Revenue

$113.1M+18.2%

Other financials

Income statement

See full

Revenue$4.3B+16.7%

Operating income$1.3B+19.8%

Net income$1.3B-6.8%

EPS (diluted)$12.23-4.5%

Balance sheet

See full

Cash & equivalents$2.5B+22.3%

Total debt$2.7B+0.1%

Total equity$31.7B+5.9%

Total assets$41.7B+9.2%

Cash flow

See full

Operating cash flow$813.0M-29.0%

CapEx$240.2M+9.7%

Free cash flow$572.8M-38.1%

Valuation

See full

Market cap$79.49B+35.1%

Enterprise value$79.73B+33.9%

P/E18.4×+5.2×

P/S5.1×+1.0×

Profitability

See full

Gross margin94.9%—

Operating margin24.7%-2.3pp

Net margin27.9%-3.5pp

FCF margin24.2%-2.9pp

Returns & leverage

See full

Return on equity14%-1.3pp

Debt / equity0.1×0.0×

Current ratio3.3×-1.3×

Where this comes from

Reported directly by Regeneron Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.

Filed: Jul 30, 2026, 6:52 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000872589-26-000025

Line item	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
U.S.	342.6	247.8	628.7	440.3
Rest of world	146.8	128.7	298.9	221.3
Global	489.4	376.5	927.6	661.6
U.S.	74.7	65.8	141.3	122.6
U.S.	53.3	41.2	99.0	72.1
Global	16.5	—	27.7	—
Global	—	—	31.3	—
	$1,642.4	$1,631.0	$3,176.9	$3,046.6

Item 1. Financial Statements (unaudited)

FAQ

What is Regeneron Pharmaceuticals's lynozyfic — revenue?: Regeneron Pharmaceuticals (REGN) reported lynozyfic — revenue of $16.5M in Q2 2026.
What does lynozyfic — revenue mean?: This metric represents the total net sales generated from the Lynozyfic product line within the company's portfolio. It reflects the market adoption, pricing power, and commercial success of this specific therapeutic asset in its targeted disease indications. Tracking these revenues allows investors to assess the product's contribution to the overall top-line growth and its lifecycle stage within the competitive pharmaceutical landscape.